TY - JOUR
T1 - PET/CT Limitations and Pitfalls in Urogenital Cancers
AU - Vasireddi, Anil
AU - Nguyen, Nghi C.
N1 - Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2021/11
Y1 - 2021/11
N2 - Hybrid FDG PET/CT plays a vital role in oncologic imaging and has been widely adopted for the staging and restaging of a variety of malignancies. Its diagnostic value in urogenital malignancies is less well-known, not at least because of the variable FDG avidity of these tumor entities, the sites of these tumors, and technical challenges associated with sequential imaging of CT and PET. PET/CT interpretation thus can be especially challenging and is associated with many pitfalls, which can lead to both false-positive and false-negative diagnoses as well as incorrect assessment of metabolic change following therapy. Currently, FDG PET/CT is not the standard of care for the initial diagnosis or staging of early-stage or low-risk urogenital cancers; however, it can help evaluate distant metastatic disease, response to therapy, and disease recurrence in high-risk patients. Knowledge of imaging features of tumor metabolic avidity and pitfalls is essential for accurate interpretation.
AB - Hybrid FDG PET/CT plays a vital role in oncologic imaging and has been widely adopted for the staging and restaging of a variety of malignancies. Its diagnostic value in urogenital malignancies is less well-known, not at least because of the variable FDG avidity of these tumor entities, the sites of these tumors, and technical challenges associated with sequential imaging of CT and PET. PET/CT interpretation thus can be especially challenging and is associated with many pitfalls, which can lead to both false-positive and false-negative diagnoses as well as incorrect assessment of metabolic change following therapy. Currently, FDG PET/CT is not the standard of care for the initial diagnosis or staging of early-stage or low-risk urogenital cancers; however, it can help evaluate distant metastatic disease, response to therapy, and disease recurrence in high-risk patients. Knowledge of imaging features of tumor metabolic avidity and pitfalls is essential for accurate interpretation.
UR - http://www.scopus.com/inward/record.url?scp=85116013442&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85116013442&partnerID=8YFLogxK
U2 - 10.1053/j.semnuclmed.2021.06.013
DO - 10.1053/j.semnuclmed.2021.06.013
M3 - Review article
C2 - 34243903
AN - SCOPUS:85116013442
SN - 0001-2998
VL - 51
SP - 611
EP - 620
JO - Seminars in Nuclear Medicine
JF - Seminars in Nuclear Medicine
IS - 6
ER -